Renub Research

Global Vaccine Market to reach USD 60 Billion, by the end of year 2022

Press Release   •   Aug 26, 2017 05:25 EDT

For More Information: http://www.renub.com/global-vaccine-market-to-reach-usd-60-billion-by-the-end-of-year-2022-49-nd.php

Global vaccine market is probable to reach US$ 60 Billion by the end of year 2022 says the recent report published by Renub Research entitled “Global Vaccines Market & Forecast” by 14 vaccines (Influenza, Cervical Cancer, Zoster, MMRV, Pneumococcal, Meningococcal, Hepatitis, Dtap, Travel and Miscellaneous, Haemophilus Influenzae Type b (Hib), Combos, Polio, Rotavirus, Varicella), number of immunized person, number of vaccines doses administered and company sales – forecast to 2022.

Vaccines Prevent Diseases

With so many diseases in the world, there needs to be something to protect people from getting sick and even dying. So, we have vaccines to protect ourselves from getting sick. In simple words, Vaccines immunize and protect people from several serious diseases such as measles, meningitis, pneumonia, Influenza, rubella and polio.

Access Full Research:http://www.renub.com/global-vaccines-market-and-forecast-14-vaccines-market-number-of-people-immunized-doses-of-vaccines-administered-1200-p.php

Era of Vaccines

A number of vaccines have been developed (e.g. cervical cancer and dengue vaccine) and several others are already on its way to hit the market at earliest (e.g. malaria and zika vaccines), making last 15 years the most productive in the history of vaccines development.

Industrialized countries already have a robust system of immunization programmes while developing countries are trying their best to implement such programmes to save a million lives.

Request a free sample copy of the report:http://www.renub.com/contactus.php

Vaccine Market Briefing

Pneumococcal vaccine is the largest segment for vaccine and it terms of value it accounts more than US$ 7 Billion in 2016. The Pneumococcal vaccine sale is primarily driven by increasing utilization of Pneumococcal vaccines products worldwide, and especially in the US, where the Advisory Committee on Immunization Practices (ACIP) strictly recommends its inoculation. While there is also a considerable boost in the market size of Cervical Cancer Vaccine as many countries around the world efficiently focused on the causalities caused by this disease, thus recommend all women must get Cervical Cancer Vaccine to prevent cervical cancer.

Analyst View

Vaccination is one of the most prominent and conservative of all healthcare interventions. It not only prevents illness and disability but also to transform, lives - giving each one a chance to grow up healthy and improve their lifestyle. Vaccines and proper vaccination save millions of lives every year.

Contact Us

Rajat Gupta

Sr. Marketing Manager

Email: info@renub.com

Phone: +1-678-302-0700

Web: www.renub.com

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.